Optimal Use of the Non-Inferiority Trial Design

[1]  G. Reboldi,et al.  Non-inferiority Trial Design in Drug Development: A Primer for Cardiovascular Healthcare Professionals , 2019, American Journal of Cardiovascular Drugs.

[2]  S. Kaul,et al.  Noninferiority Designed Cardiovascular Trials in Highest-Impact Journals , 2019, Circulation.

[3]  John P. A. Ioannidis,et al.  Bayes factors for superiority, non-inferiority, and equivalence designs , 2019, BMC Medical Research Methodology.

[4]  Brian P Hobbs,et al.  Detecting and accounting for violations of the constancy assumption in non-inferiority clinical trials , 2018, Statistical methods in medical research.

[5]  G. Reboldi,et al.  Why switch from warfarin to NOACs? , 2016, Internal and Emergency Medicine.

[6]  S. Pocock,et al.  Design of Major Randomized Trials: Part 3 of a 4-Part Series on Statistics for Clinical Trials. , 2015, Journal of the American College of Cardiology.

[7]  R. Lewis,et al.  Noninferiority Trials: Is a New Treatment Almost as Effective as Another? , 2015, JAMA.

[8]  Wenyaw Chan,et al.  Statistical Methods in Medical Research , 2013, Model. Assist. Stat. Appl..

[9]  Sanjay Kaul,et al.  Non-inferiority study design: lessons to be learned from cardiovascular trials. , 2012, European heart journal.

[10]  S. Pocock,et al.  Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement. , 2006, JAMA.

[11]  J. Schumi,et al.  TRIALS REVIEW Open Access , 2022 .

[12]  Arno W. Hoes,et al.  Room for Improvement in Conducting and Reporting Non-Inferiority Randomized Controlled Trials on Drugs: A Systematic Review , 2010, PloS one.

[13]  A. Hoes,et al.  Interpretation and Inference in Noninferiority Randomized Controlled Trials in Drug Research , 2010, Clinical pharmacology and therapeutics.

[14]  Draft Guidance.  Guidance for Industry Non-Inferiority Clinical Trials , 2010 .

[15]  S. Yusuf,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[16]  Anika Ashok,et al.  Guidance for Industry by U.S. Department of Health and Human Services—Food and Drug Administration—Center for Biologics Evaluation and Research (CBER)—February 1999 , 2009 .

[17]  I. Scott.  Non‐inferiority trials: determining whether alternative treatments are good enough , 2009, The Medical journal of Australia.

[18]  T. Ebner,et al.  The Metabolism and Disposition of the Oral Direct Thrombin Inhibitor, Dabigatran, in Humans , 2008, Drug Metabolism and Disposition.

[19]  K. Rathgen,et al.  The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. , 2007, British journal of clinical pharmacology.

[20]  A. Gray,et al.  European Medicines Agency Pre-Authorisation Evaluation of Medicines for Human Use , 2008 .

[21]  S. Pocock.  The pros and cons of noninferiority trials , 2003, Fundamental & clinical pharmacology.

[22]  Mark Rothmann,et al.  Design and analysis of non‐inferiority mortality trials in oncology , 2002, Statistics in medicine.

[23]  O. Benavente,et al.  Antithrombotic Therapy To Prevent Stroke in Patients with Atrial Fibrillation , 1999, Annals of Internal Medicine.

[24]  E. Holmgren,et al.  Establishing equivalence by showing that a specified percentage of the effect of the active control over placebo is maintained. , 1999, Journal of biopharmaceutical statistics.

[25]  J. Fleiss.  General design issues in efficacy, equivalency and superiority trials. , 1992, Journal of periodontal research.

[26]  T C Chalmers,et al.  A comparison of statistical methods for combining event rates from clinical trials. , 1989, Statistics in medicine.